American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary
DAIC
FEBRUARY 29, 2024
The Be Active Randomized Clinical Trial Zilebesiran in Combination with a Standard-of-care Antihypertensive in Patients With Inadequately Controlled Hypertension: Primary Results From the Phase 2 Kardia-2 Study Efficacy and Safety of Olezarsen in Patients with Hypertriglyceridemia and High Cardiovascular Risk: Primary Results of the BRIDGE-TIMI 73a (..)
Let's personalize your content